RhumbLine Advisers’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

RhumbLine Advisers’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-809	Closed	-$120K	–	3131
2021 Q1	$120K	Sell	809 -21	-3%	-$3.81K	﹤0.01%	2915
2020 Q4	$116K	Buy	830 +62	+8%	+$10K	﹤0.01%	2950
2020 Q3	$117K	Sell	768 -22	-3%	-$3.59K	﹤0.01%	2842
2020 Q2	$139K	Buy	+790	New	+$132K	﹤0.01%	2881
2015 Q2	–	Sell	-53	Closed	-$54K	–	3104
2015 Q1	$54K	Buy	53 +10	+23%	+$33K	﹤0.01%	2995
2014 Q4	$142K	Buy	43 +2	+5%	+$6.13K	﹤0.01%	2897
2014 Q3	$120K	Buy	41 +4	+11%	+$13.2K	﹤0.01%	2905
2014 Q2	$140K	Buy	+37	New	+$139K	﹤0.01%	2937

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's NBSE Position: Q2 2021 in Review

RhumbLine Advisers sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2021, closing a stake of 809 shares — an estimated $120K sold.

RhumbLine Advisers first reported a position in NBSE in Q2 2014 and held it in 8 quarters. The position peaked at $142K in Q4 2014. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2021.

RhumbLine Advisers reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 809 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $120K.
RhumbLine Advisers first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 8 quarters.
RhumbLine Advisers's NeuBase Therapeutics, Inc. Common Stock position peaked at $142K in Q4 2014.
57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.